SPIA
LXRX icon

Steward Partners Investment Advisory’s Lexicon Pharmaceuticals LXRX Stock Holding History

Steward Partners Investment Advisory’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$780 Hold
500
– – ﹤0.01% 4220
2025
Q4 		$575 Sell
500
-10,285
-95% -$14.1K ﹤0.01% 4139
2025
Q3 		$14.6K Sell
10,785
-10,638
-50% -$12.1K ﹤0.01% 3233
2025
Q2 		$20.3K Buy
21,423
+100
+0.5% +$65 ﹤0.01% 2920
2025
Q1 		$9.83K Buy
21,323
+20,923
+5,231% +$13.2K ﹤0.01% 3104
2024
Q4 		$295 Hold
400
– – ﹤0.01% 3889
2024
Q3 		$628 Buy
+400
New +$712 ﹤0.01% 3572
2020
Q4 		– Sell
-2,600
Closed -$4K – 2952
2020
Q3 		$4K Hold
2,600
– – ﹤0.01% 2434
2020
Q2 		$5K Hold
2,600
– – ﹤0.01% 2273
2020
Q1 		$5K Hold
2,600
– – ﹤0.01% 2081
2019
Q4 		$10K Hold
2,600
– – ﹤0.01% 2015
2019
Q3 		$7K Hold
2,600
– – ﹤0.01% 2135
2019
Q2 		$16K Buy
+2,600
New +$15.6K ﹤0.01% 1790
2018
Q4 		– Sell
-2,600
Closed -$28K – 1560
2018
Q3 		$28K Hold
2,600
– – ﹤0.01% 1407
2018
Q2 		$31K Hold
2,600
– – ﹤0.01% 1284
2018
Q1 		$22K Sell
2,600
-400
-13% -$3.7K ﹤0.01% 1294
2017
Q4 		$29K Buy
+3,000
New +$31.2K ﹤0.01% 1003

Other funds holding LXRX

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Steward Partners Investment Advisory's LXRX Position: Q1 2026 in Review

Steward Partners Investment Advisory held its Lexicon Pharmaceuticals (LXRX) position steady in Q1 2026 at 500 shares worth $780. The position accounts for ﹤0.01% of the portfolio, ranked #4220.

Steward Partners Investment Advisory first reported a position in LXRX in Q4 2017 and has held it in 17 quarters since. The position peaked at $31K in Q2 2018. 136 funds tracked by Wall St. Rank hold LXRX as of Q1 2026.

  • Steward Partners Investment Advisory held 500 shares of Lexicon Pharmaceuticals worth $780 as of Q1 2026.
  • Steward Partners Investment Advisory left its Lexicon Pharmaceuticals share count unchanged in Q1 2026.
  • Lexicon Pharmaceuticals made up ﹤0.01% of Steward Partners Investment Advisory's portfolio in Q1 2026, its #4220 holding.
  • Steward Partners Investment Advisory first reported a position in Lexicon Pharmaceuticals in Q4 2017 and has held it in 17 quarters since.
  • Steward Partners Investment Advisory's Lexicon Pharmaceuticals position peaked at $31K in Q2 2018.
  • 136 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2026.

Based on Steward Partners Investment Advisory's 13F filing for Q1 2026, filed 8 May 2026.